41
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The Alzheimer’s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          INTRODUCTION

          The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer’s disease (AD) clinical trials. ADNI-3, beginning August 1, 2016, is a five year renewal of the current ADNI-2 study.

          METHODS

          ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment (MCI) and AD using innovative technologies such as tau imaging, magnetic resonance imaging (MRI) sequences for connectivity analyses, and a highly-automated immunoassay platform and mass spectroscopy approach for CSF biomarker analysis. A Systems Biology/Pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography (PET) scanning will be standardized using by the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.

          RESULTS

          Multi-modal analyses will provide insight into AD pathophysiology and disease progression.

          DISCUSSION

          ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

          Related collections

          Author and article information

          Journal
          101231978
          33173
          Alzheimers Dement
          Alzheimers Dement
          Alzheimer's & dementia : the journal of the Alzheimer's Association
          1552-5260
          1552-5279
          13 June 2017
          05 December 2016
          May 2017
          01 May 2018
          : 13
          : 5
          : 561-571
          Affiliations
          [a ]Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA
          [b ]Department of Radiology, University of California, San Francisco, CA, USA
          [c ]Department of Medicine, University of California, San Francisco, CA, USA
          [d ]Department of Psychiatry, University of California, San Francisco, CA, USA
          [e ]Department of Neurology, University of California, San Francisco, CA, USA
          [f ]Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA
          [g ]Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA
          [h ]Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA
          [i ]Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA
          [j ]Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
          [k ]Department of Radiology, Mayo Clinic, Rochester, MN, USA
          [l ]Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
          [m ]Department of Neurology, Mayo Clinic, Rochester, MN, USA
          [n ]Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
          [o ]Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
          [p ]Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA
          [q ]Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
          [r ]Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
          [s ]Alzheimer’s Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
          [t ]Udall Parkinson’s Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
          [u ]Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
          Author notes
          [* ]Corresponding author. Tel. 415-221-4810 x 3642; Fax:415-668-2864. michael.weiner@ 123456ucsf.edu
          Article
          PMC5536850 PMC5536850 5536850 nihpa841893
          10.1016/j.jalz.2016.10.006
          5536850
          27931796
          fedd535b-aebb-4871-b613-d0dc6c6458d3
          History
          Categories
          Article

          Alzheimer’s disease,tau imaging,amyloid phenotyping,Centiloid method,Brain Health Registry,functional connectivity,clinical trial biomarkers

          Comments

          Comment on this article